US 11,229,690 B2 · Bordetella vaccine

Abstract

The present invention provides genetically engineered strains of the Bordetella species to include one or more mutations preventing expression of the gene encoding the Bordetella Sigma Regulator (also referred to as “bsr,” “btrS,” and “brpL”), compositions and vaccines thereof, and the use of such engineered strains in methods to protect against Bordetella spp, including but not limited to Bordetella bronchiseptica, B. pertussis, B. parapertussis, B. homelsii, or B. avium. In some aspects, the present invention provides the Bordetella bronchiseptica strain RB50Δbsr, compositions and vaccines thereof, and the use of Bordetella bronchiseptica strain RB50Δfer in methods to protect against Bordetella spp, including but not limited to Bordetella bronchiseptica, B. pertussis, B. parapertussis, B. homelsii, or B. avium.

Claims18

Dependent claims

A vaccine composition effective for inducing sterilizing immunity against Bordetella bronchiseptica, Bordetella pertussis, or Bordetella parapertussis in a vertebrate subject, the vaccine composition comprising an effective amount of an isolated strain of a Bordetella species and a pharmaceutically acceptable carrier suitable for administration to a vertebrate subject,

wherein the isolated strain of the Bordetella species consists of a single mutation,
wherein the single mutation prevents expression of the bsr sigma factor (also known as the btrS gene product or the brpL gene product),
wherein the Bordetella species is selected from Bordetella bronchiseptica, Bordetella pertussis, or Bordetella parapertussis, and
wherein sterilizing immunity prevents colonization in the lung and/or nasal cavity of the subject and prevents further transmission.

1 more element

Dependencies are inferred from the claim text.

Bordetella vaccine

Life of this patent

Bordetella vaccine

Life of this patent

Abstract

Claims18